Cost comparison of school-based mass drug administration of albendazole and ivermectin versus albendazole alone for soil-transmitted helminth control in Uganda

The co-administration of albendazole and ivermectin (ALB-IVM) is recommended for the treatment of soil-transmitted helminth (STH) infections, especially where the prevalence of Trichuris trichiura is high. Before large-scale implementation can be considered, feasibility, acceptability and required resources and investments for the mass drug administration (MDA) of ALB-IVM compared with albendazole (ALB) alone should be assessed. This study, conducted in two districts in south-western Uganda, aimed to assess and compare the costs of school-based MDA with ALB-IVM (MDA-ALB-IVM) versus the routinely used ALB alone (MDA-ALB) on a small scale (targeting around 2,500 children per treatment arm per district). We applied a micro-costing (mixed top-down and bottom-up) approach to assess the financial costs from a health system perspective, as well as the opportunity costs of donated ALB. The total (financial and opportunity) costs of MDA-ALB-IVM were higher than those of MDA-ALB ($10,793 for MDA-ALB-IVM versus $4,458 for MDA-ALB in Kabale district and $14,445 versus $5,765 in Kisoro, respectively). The presence of informed consent and assent required for MDA-ALB-IVM (as ALB-IVM is still considered a new therapy for STH infections in Uganda) increased the number of days and resources including personnel requirements for training and drug distribution. Furthermore, adequate community sensitization and the involvement of community health workers (i.e., village health teams in Uganda) and local community leaders appeared to be essential to achieve high treatment coverage. The scenario analysis showed that, in the absence of the informed consent and assent process, the total incremental costs of MDA-ALB-IVM compared with MDA-ALB could decrease by 31%-36% in the two districts. This study identifies key cost drivers and offers insights for the wider implementation of ALB-IVM co-administration.

Authors

Institutions

Publication Details

Journal
PLoS neglected tropical diseases
Published
2026-01-14
DOI
https://doi.org/10.1371/journal.pntd.0013913
Primary Topic
Parasites and Host Interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost comparison of school-based mass drug administration of albendazole and ivermectin versus albendazole alone for soil-transmitted helminth control in Uganda

Tanja Barth‐Jaeggi, Harsh Vivek Harkare, Eveline Hürlimann, Prudence Beinamaryo et al.
PLoS neglected tropical diseases
Parasites and Host Interactions
article

Cost comparison of school-based mass drug administration of albendazole and ivermectin versus albendazole alone for soil-transmitted helminth control in Uganda

Tanja Barth‐Jaeggi, Harsh Vivek Harkare, Eveline Hürlimann, Prudence Beinamaryo, Hilda Kyarisiima, Leonsio Matagi, Fabrizio Tediosi, Yuling Lin, Jennifer Keiser, Isaac Byarugaba, Peter Steinmann
article en

Abstract

The co-administration of albendazole and ivermectin (ALB-IVM) is recommended for the treatment of soil-transmitted helminth (STH) infections, especially where the prevalence of Trichuris trichiura is high. Before large-scale implementation can be considered, feasibility, acceptability and required resources and investments for the mass drug administration (MDA) of ALB-IVM compared with albendazole (ALB) alone should be assessed. This study, conducted in two districts in south-western Uganda, aimed to assess and compare the costs of school-based MDA with ALB-IVM (MDA-ALB-IVM) versus the routinely used ALB alone (MDA-ALB) on a small scale (targeting around 2,500 children per treatment arm per district). We applied a micro-costing (mixed top-down and bottom-up) approach to assess the financial costs from a health system perspective, as well as the opportunity costs of donated ALB. The total (financial and opportunity) costs of MDA-ALB-IVM were higher than those of MDA-ALB ($10,793 for MDA-ALB-IVM versus $4,458 for MDA-ALB in Kabale district and $14,445 versus $5,765 in Kisoro, respectively). The presence of informed consent and assent required for MDA-ALB-IVM (as ALB-IVM is still considered a new therapy for STH infections in Uganda) increased the number of days and resources including personnel requirements for training and drug distribution. Furthermore, adequate community sensitization and the involvement of community health workers (i.e., village health teams in Uganda) and local community leaders appeared to be essential to achieve high treatment coverage. The scenario analysis showed that, in the absence of the informed consent and assent process, the total incremental costs of MDA-ALB-IVM compared with MDA-ALB could decrease by 31%-36% in the two districts. This study identifies key cost drivers and offers insights for the wider implementation of ALB-IVM co-administration.

PLoS neglected tropical diseasesVol. 20(1)
Swiss Tropical and Public Health Institute (CH), University of Basel (CH), Ministry of Health (UG), Makerere University (UG)
Good health and well-being
Openalex Percentile: Top 85%
Parasites and Host Interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.